1. Home
  2. VTRS vs CX Comparison

VTRS vs CX Comparison

Compare VTRS & CX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTRS
  • CX
  • Stock Information
  • Founded
  • VTRS 1961
  • CX 1906
  • Country
  • VTRS United States
  • CX Mexico
  • Employees
  • VTRS N/A
  • CX N/A
  • Industry
  • VTRS Medicinal Chemicals and Botanical Products
  • CX Building Materials
  • Sector
  • VTRS Health Care
  • CX Industrials
  • Exchange
  • VTRS Nasdaq
  • CX Nasdaq
  • Market Cap
  • VTRS 11.1B
  • CX 12.2B
  • IPO Year
  • VTRS N/A
  • CX 1999
  • Fundamental
  • Price
  • VTRS $10.37
  • CX $9.34
  • Analyst Decision
  • VTRS Hold
  • CX Buy
  • Analyst Count
  • VTRS 6
  • CX 7
  • Target Price
  • VTRS $11.17
  • CX $9.81
  • AVG Volume (30 Days)
  • VTRS 7.1M
  • CX 9.4M
  • Earning Date
  • VTRS 11-06-2025
  • CX 10-28-2025
  • Dividend Yield
  • VTRS 4.64%
  • CX 0.92%
  • EPS Growth
  • VTRS N/A
  • CX 856.63
  • EPS
  • VTRS N/A
  • CX 0.10
  • Revenue
  • VTRS $14,115,700,000.00
  • CX $15,675,737,000.00
  • Revenue This Year
  • VTRS N/A
  • CX $2.64
  • Revenue Next Year
  • VTRS $1.61
  • CX $4.82
  • P/E Ratio
  • VTRS N/A
  • CX $9.02
  • Revenue Growth
  • VTRS N/A
  • CX N/A
  • 52 Week Low
  • VTRS $6.85
  • CX $4.89
  • 52 Week High
  • VTRS $13.55
  • CX $9.97
  • Technical
  • Relative Strength Index (RSI)
  • VTRS 61.57
  • CX 52.12
  • Support Level
  • VTRS $10.30
  • CX $9.11
  • Resistance Level
  • VTRS $10.52
  • CX $9.75
  • Average True Range (ATR)
  • VTRS 0.21
  • CX 0.24
  • MACD
  • VTRS 0.05
  • CX -0.02
  • Stochastic Oscillator
  • VTRS 81.82
  • CX 37.30

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

About CX Cemex S.A.B. de C.V. Sponsored ADR

Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and also provide related services and reliable construction-related services to customers and communities and maintain business relationships in more than 60 countries throughout the world. The company operates in different parts of the world, with operations in Mexico, the United States, the EMEA region and the SCA&C region.

Share on Social Networks: